We provide cGMP/clinical-grade induced pluripotent stem cells (iPSCs) and advanced differentiation, including β Cells AiB, for clinical and commercial applications from Phase 1 to Phase 3 and beyond. Our San Diego-based, cGMP-compliant modular facility ensures 21CFR-compliant, ethically sourced tissue procurement, supporting scalable, high-quality iPSC production.
Using integration-free, mRNA-based reprogramming, we offer efficient and risk-free iPSC generation and differentiation, ideal for next-generation cell therapies. Our private clinical-grade iPSC banking ensures secure, personalized storage for future treatments.
Through custom CDMO partnerships, we develop tailored cellular therapeutics while our AIoT automation solutions optimize laboratory research and pharmaceutical manufacturing, enhancing precision and efficiency.
Partner with us to drive the future of regenerative medicine and advanced cell therapy.